FDA Updates Highlighting the Latest Cancer Treatments : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
New data tool could bring RNA sequencing into standard clinical practice, improving diagnosis and treatment
The theory holding “cell dedifferentiation” as a hallmark of cancer and the less-well accepted “evolutionary” reversal theory are difficult to tease out experimentally. The authors…
The 2025 American Cancer Society Annual Report Showed incidence rates are increasing for many cancer types and disparities remain regarding cancer mortality.
The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.
The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.
The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.
Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, with…
on has been widely studied and implemented in the thoracic and lumbar spine. However less literature exists regarding the use of computer-assisted navigation for posterior…
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Explore JAAOS peer-reviewed articles covering the expanse of orthopaedic medicine and representing over 39,000 members of the AAOS. Subscribe today!